Gayle A Taylor

US Patent:

7732432, Jun 8, 2010

Filed:

Jan 16, 2004

Appl. No.:

10/540757

Inventors:

Amjad Ali - Piscataway NJ, US
James M. Balkovec - Martinsville NJ, US
Donald W. Graham - Mountainside NJ, US
Mark L. Greenlee - Plainfield NJ, US
Gayle E. Taylor - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/56
C07J 5/00

US Classification:

514178, 514179, 552570

Abstract:

The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

US Patent:

7737295, Jun 15, 2010

Filed:

Apr 8, 2005

Appl. No.:

11/578694

Inventors:

Amjad Ali - Freehold NJ, US
Joann Bohn - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07C 261/00
C07C 211/00
A01N 47/10

US Classification:

560115, 560132, 564336, 564337, 514476

Abstract:

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, Aand A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

US Patent:

7745657, Jun 29, 2010

Filed:

May 15, 2006

Appl. No.:

11/919195

Inventors:

Amjad Ali - Freehold NJ, US
Mark L. Greenlee - Plainfield NJ, US
Carol A. McVean - Lansdale PA, US
Robert S. Meissner - Schwenksville PA, US
Gayle E. Taylor - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07C 261/00

US Classification:

560115, 560 24, 560 27, 560163, 560164

Abstract:

The present invention is directed to D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

US Patent:

7781426, Aug 24, 2010

Filed:

Dec 29, 2006

Appl. No.:

12/087184

Inventors:

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/422
A61K 31/5377
A61K 31/541
A61K 31/496
A61K 31/443
A61K 31/4525
A61K 31/55
C07D 403/02
C07D 413/02
C07D 417/02
C07D 401/02

US Classification:

5142171, 514376, 5142368, 5142278, 51425402, 514340, 514326, 548230, 544137, 544 60, 544369, 5462714, 546209, 540603

Abstract:

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or Ris a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or Ris also a cyclic group.

US Patent:

8193365, Jun 5, 2012

Filed:

Jun 14, 2010

Appl. No.:

12/815146

Inventors:

Amjad Ali - Freehold NJ, US
Joann Bohn - North Plainfield NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle Taylor - Red Bank NJ, US
Christopher Thompson - Clark NJ, US
Nazia Quraishi - Vienna VA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 261/02
C07D 209/04
C07D 307/93
A01N 57/26
A01N 57/00

US Classification:

546348, 548490, 548240, 549462

Abstract:

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, Aand A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

US Patent:

8334290, Dec 18, 2012

Filed:

Oct 30, 2006

Appl. No.:

12/083324

Inventors:

Amjad Ali - Freehold NJ, US
Julianne A. Hunt - Scotch Plains NJ, US
Florida Kallashi - Laurence Harbor NJ, US
Jennifer Kowalchick - Clark NJ, US
Dooseop Kim - Westfield NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Ramzi F. Sweis - Franklin Park NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Liya Chen - East Brunswick NJ, US
Nazia Quraishi - Vienna VA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/496
A61K 31/497
A61K 31/443
A61K 31/421
C07D 239/42
C07D 413/14
C07D 211/32
C07D 213/26
C07D 263/57

US Classification:

5142531, 51425402, 514318, 514321, 514375, 544332, 544368, 546194, 546198, 548224

Abstract:

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

US Patent:

20050245588, Nov 3, 2005

Filed:

Sep 17, 2003

Appl. No.:

10/527615

Inventors:

Amjad Ali - Piscataway NJ, US
Susan Aster - Teaneck NJ, US
James Balkovec - Martinsville NJ, US
Donald Graham - Mountainside NJ, US
Julianne Hunt - Scotch Plains NJ, US
Florida Kallashi - Yonkers NY, US
Peter Sinclair - Scotch Plains NJ, US
James Tata - Westfield NJ, US
Gayle Taylor - Jersey City NJ, US
Joung Goulet - Westfield NJ, US

International Classification:

C07D231/54
A61K031/4162

US Classification:

514406000, 548358500

Abstract:

The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

US Patent:

20060040999, Feb 23, 2006

Filed:

Jul 1, 2005

Appl. No.:

11/173295

Inventors:

Amjad Ali - Freehold NJ, US
Joann Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter Sinclair - Scotch Plains NJ, US
Gayle Taylor - Jersey City NJ, US
Christopher Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron Smith - Lawrenceville NJ, US
Julianne Hunt - Scotch Plains NJ, US
Adrian Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

International Classification:

A61K 31/421
C07D 263/16

US Classification:

514376000, 548229000

Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.